Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38)

ObjectivesTo characterise clinically translatable long-circulating (BR38) and VEGFR2-targeted (BR55) microbubbles (MB) and to assess their ability to discriminate breast cancer models with different aggressiveness.MethodsThe circulation characteristics of BR38 and BR55 were investigated in healthy mice. The relative blood volume (rBV) of MDA-MB-231 (n = 5) or MCF-7 (n = 6) tumours was determined using BR38. In the same tumours in-vivo binding specificity of BR55 was tested and VEGFR2 expression assessed. Data validation included quantitative immunohistological analysis.ResultsBR38 had a longer blood half-life than BR55 (>600 s vs. 218 s). BR38-enhanced ultrasound showed greater vascularisation in MDA-MB-231 tumours (p = 0.022), which was in line with immunohistology (p = 0.033). In-vivo competitive binding experiments proved the specificity of BR55 to VEGFR2 (p = 0.027). Binding of BR55 was significantly higher in MDA-MB-231 than in MCF-7 tumours (p = 0.049), which corresponded with the VEGFR2 levels found histologically (p = 0.015). However, differences became smaller when normalising the levels of BR55 to the rBV.ConclusionsBR38 and BR55 are well suited to characterising and distinguishing breast cancers with different angiogenesis and aggressiveness. Long-circulating BR38 MB allow extensive 3-dimensional examinations of larger or several organs. BR55 accumulation faithfully reflects the VEGFR2 status in tumours and depicts even small differences in angiogenesis.

[1]  D. Mennerich,et al.  Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway , 2007, BMC Cancer.

[2]  Sanjiv S Gambhir,et al.  US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. , 2008, Radiology.

[3]  Yan Leng,et al.  Abelson Interactor Protein-1 Positively Regulates Breast Cancer Cell Proliferation, Migration, and Invasion , 2007, Molecular Cancer Research.

[4]  Wolfhard Semmler,et al.  Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects , 2008, Molecular Cancer Therapeutics.

[5]  Vyacheslav Kalchenko,et al.  Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. , 2006, Cancer research.

[6]  S. Kaul,et al.  Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. , 2000, Circulation.

[7]  Sanjiv S Gambhir,et al.  Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). , 2010, Radiology.

[8]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Stuart Foster,et al.  Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.

[10]  Corinne Balleyguier,et al.  New potential and applications of contrast-enhanced ultrasound of the breast; own investigations and review of the literature , 2009 .

[11]  M. Shibuya.  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.

[12]  Sanjiv S Gambhir,et al.  Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. , 2008, Radiology.

[13]  W. Kaiser,et al.  Breast magnetic resonance imaging: principles and techniques. , 2007, Seminars in roentgenology.

[14]  M. Miyazaki,et al.  Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. , 2001, Journal of hepatology.

[15]  Jonathan R. Lindner,et al.  Microbubbles in medical imaging: current applications and future directions , 2004, Nature Reviews Drug Discovery.

[16]  Isabelle Tardy,et al.  BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis , 2010, Investigative radiology.

[17]  C. Merritt.  Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer , 2009 .

[18]  Fabian Kiessling,et al.  Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. , 2003, Cancer research.

[19]  E. Marinelli,et al.  A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. , 2005, Protein engineering, design & selection : PEDS.

[20]  S. Delorme,et al.  Pharmacodynamics of Streptavidin-Coated Cyanoacrylate Microbubbles Designed for Molecular Ultrasound Imaging , 2008, Investigative radiology.

[21]  Katherine W. Ferrara,et al.  Lipid-Shelled Vehicles: Engineering for Ultrasound Molecular Imaging and Drug Delivery , 2009 .

[22]  A. Klibanov,et al.  Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. , 2005, Bioconjugate chemistry.

[23]  M. Duncan,et al.  Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. , 2008, Cancer research.

[24]  Wolfhard Semmler,et al.  Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. , 2010, European journal of radiology.

[25]  Rolf A. Brekken,et al.  Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature , 2007, Clinical Cancer Research.

[26]  E. Marinelli,et al.  A flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. , 2006, Biopolymers.

[27]  F. Kiessling,et al.  Functional and molecular ultrasound imaging: concepts and contrast agents. , 2009, Current medicinal chemistry.

[28]  Paul A Dayton,et al.  Molecular ultrasound imaging using microbubble contrast agents. , 2007, Frontiers in bioscience : a journal and virtual library.

[29]  A R Jayaweera,et al.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. , 1998, Circulation.

[30]  J. Llull,et al.  Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. , 2000, Investigative radiology.

[31]  John C Gore,et al.  Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[32]  S. Cherkaoui,et al.  A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. , 2010, Bioconjugate chemistry.

[33]  M. Suematsu,et al.  Mechanism of Hepatic Parenchyma-Specific Contrast of Microbubble-Based Contrast Agent for Ultrasonography: Microscopic Studies in Rat Liver , 2007, Investigative Radiology.

[34]  Sanjiv S Gambhir,et al.  Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. , 2008, Radiology.

[35]  Wolfhard Semmler,et al.  Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. , 2008, Cancer research.